1 / 71

Disclosure Slide

Disclosure Slide. We have no financial relationships with any commercial interest related to the content of this activity. Pertussis and Pertussis Vaccination: Why All the Whoop-la?. A Summary for South Carolina Medical Providers Riyadh D. Muhammad, MD, MPH – Pediatrician

jess
Download Presentation

Disclosure Slide

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Disclosure Slide We have no financial relationships with any commercial interest related to the content of this activity

  2. Pertussis and Pertussis Vaccination: Why All the Whoop-la? A Summary for South Carolina Medical Providers Riyadh D. Muhammad, MD, MPH – Pediatrician Helen L. Huber, MSN - Pediatric Nurse Practitioner Bureau of Disease Control South Carolina Department of Health and Environmental Control

  3. Source: W. Orenstein. An overview of Vaccinology; 2009 Clinical Vaccinology Course, Atlanta.

  4. Sounds of Pertussis Whooping Child Whooping Adult

  5. Overview • Pertussis Surveillance Data • Clinical Considerations • Background • Clinical Features • Diagnosis • Treatment • Reporting cases to DHEC • Vaccine • Vaccines available • Recommendations • Coverage rates • Safety

  6. Reported Pertussis Cases* U.S., 1922-2009† DTaP for all doses (1997) DTaP for doses 4 & 5 (1992) DTP (1949) Tdap (2005) *National Notifiable Diseases Surveillance System (NNDSS) †2009 data provisional Ref: S. Roush, NIC 2010

  7. Reported Pertussis Cases* U.S., 1980-2009† Tdap (2005) 1997: PCR included in case definition *National Notifiable Diseases Surveillance System (NNDSS) †2009 data provisional Ref: S. Roush, NIC 2010

  8. U.S. Pertussis Cases, 2010 Ref: CDC. Unpublished data.

  9. South Carolina Rate

  10. S.C. Pertussis Cases, 2010

  11. South Carolina, 2010

  12. South Carolina

  13. Pertussis • Fastidious gram-negative bacillus, Bordetella pertussis • Severe, debilitating cough illness lasting weeks to months (“100 day cough”) • Characterized by paroxysms of cough, inspiratory whoop, vomiting; apnea in young infants

  14. Pertussis • Highly contagious • Transmission by contact with secretions, droplets from nose or mouth • Vaccine preventable, but poorly controlled • Despite high childhood vaccine coverage, pertussis remains a problem in S.C. and the U.S.

  15. Pertussis • Worldwide occurrence • Affects all ages, even vaccinated persons • Morbidity and mortality complications most common among infants • Transmission from parents, household members • Recommendation for cocooning vaccination approach • Persistent cough itself can cause complications

  16. Pertussis Clinical Features • Incubation period 5-10 days (range 4-21 days) • Insidious onset, similar to minor URI with nonspecific cough • Fever minimal or absent • Pertussis presentation varies depending upon age, existing immunity • Classically characterized by • Paroxysms of cough • Inspiratory whoop • Vomiting

  17. Timeline of Pertussis Symptoms • Catarrhal stage 1-2 weeks • Mild URI, progresses to cough • Most contagious stage • Paroxysmal 1-6 weekscough stage • Whooping, vomiting • Convalescence Weeks to months • Gradual resolution

  18. Pertussis Epidemiology • Reservoir Humans • Transmission Respiratory droplets • Communicability Maximum in catarrhal stage Secondary attack rate up to 80%

  19. Pertussis Among Adolescents and Adults • Disease often milder compared to infants and children • Persons with mild disease may transmit the infection • Infection may be asymptomatic, or present as classic pertussis • Pertussis is unrecognized, underreported • Asymptomatic infections are 4 to 22 times more common than symptomatic infections • Symptomatic adolescents and adults are the major source of infection in unvaccinated children

  20. Pertussis Among Infants • Most severe disease • Infants under 6 months have an atypical presentation • Short catarrhal stage • Longer period of convalescence • Absence of whoop • Prominent symptoms can be • Gagging • Gasping • Apnea • Can lead to sudden unexplained death

  21. Let’s Protect Our Infants!Pertussis Deaths in the U.S., 2004-2006 Age at onset <3 mos 24 32 13 69 (84%) >3 mos 3 7 3 13 (16%) Total 27 39 16 82 2004 2005 2006 Total CDC, unpublished data, 2007

  22. Source of Pertussis Among Infants • 616 cases of pertussis in infants • Source identified in 264 (43%) • Parents 47% • Siblings 20% • Grandparents 8% • Other 25% Ref: Bisgard et al. PIDJ 2004;23:985-989.

  23. Pertussis Complications Condition Pneumonia SeizuresEncephalopathy Hospitalization Death Percent reported 4.9 0.7 0.1 16 0.2 *Cases reported to CDC 2001-2003 (N=28,998)

  24. Pertussis Complications • Seizures • Encephalopathy • Syncope • Rib Fractures • Incontinence Courtesy of T. Schlenker, Children's Hospital of Wisconsin

  25. Pertussis Diagnosis • Culture • Polymerase chain reaction (PCR) • Serology • Direct fluorescent antibody (DFA) • DFA and serology might be clinically useful • Cannot be used for case confirmation for reporting

  26. Pertussis Diagnosis Is currently complicated by: • Stage of disease (catarrhal, paroxysmal, convalescent) • Antimicrobial administration • Vaccination status • Quality/timely collection of clinical specimen • Transport conditions • Contamination of clinical specimen • Lack of clinically validated and standardized tests

  27. Optimal Timing for Pertussis Diagnostic Testing Communicable Period Convalescent Stage Paroxysmal Stage Incubation Period Catarrhal Stage -3 0 2 8 12 Weeks Bacterial Culture Symptom Onset PCR Serology

  28. PCR

  29. Culture • Isolation drastically declines after: • - 2 weeks of cough • - Antimicrobial or vaccine administration • - Inappropriate collection/transport /growth conditions

  30. ‘Pseudo’ Outbreaks of Pertussis: Pitfalls of PCR

  31. Problems Identified in Pseudo Pertussis Outbreaks • Over reliance on PCR • Single, non-specific DNA targets • Few cultures were performed • Testing ill persons without typical pertussis symptoms • Viruses, parapertussis, Chlamydia, Mycoplasma, etc • Contamination of PCR tests via • Specimens from true cases • Pertussis vaccines • Inappropriate specimen handling

  32. Obtain PCR and Culture • CDC and DHEC recommend culture along with your PCR • PCR should be used in conjunction with and not in place of culture • Pertussis culture is • Cheap • Facilitates validation of PCR results • Keeps PCR ‘honest’ • False positives • Contamination • None are FDA approved

  33. Collecting Pertussis Specimens • Nasopharyngeal (NP) wash or swab • Use for culture, PCR • Throat swabs, cotton-tipped swabs not acceptable and inhibit growth of B. pertussis *A video of NP swab collection is available at: http://video.cdc.gov/asxgen/nip/isd/swabdemo.wmv

  34. Collecting NP Swabs for Pertussis Testing • Requires 2 Dacron tipped swabs with flexible shafts per patient • One placed in Regan Lowe Transport Media at bedside (used for culturing) • One placed in a sterile tube without media (used for PCR) • Avoid contamination • Failure to follow these procedures can cause • False negatives • False positives

  35. Antibiotic Treatment • Macrolide antibiotics first-line • 5-day course of azithromycin, or • 7-day course of clarithromycin, or • 14-day course of erythromycin • Alternative is a14-day course of TMP/SMX • Treat persons >1 year within 3 weeks of cough onset (up to 90% clear infection in 3-4 weeks) • Treat persons <1 year within 6 weeks of cough onset (infectious longer) • Postexposure antibiotics to case contacts within 3 weeks of exposure

  36. Fairfield, Lexington, Newberry, Richland 803-576-2749 Chester, Lancaster, York 803-286-9948

  37. Reporting Pertussis to DHEC • Providers required to report • Not the sole responsibility of laboratories • Report suspected or confirmed cases • No need to wait for lab confirmation • DHEC assists providers • Diagnostic testing • Outbreak investigation and control • Identification of source cases • Contact tracing for antibiotic prophylaxis • Vaccine resources

  38. Pertussis Case Investigation • Suspect pertussis infection • Infant with: initially URI symptoms*, coughing, apnea, gagging, gasping, hypoxia, seizures; contact with a coughing individual • Older child or adult with: cough illness, paroxyms, whooping, post-tussive vomiting, prolonged cough; cases may be diagnosed with ‘bronchitis’ • Inform local DHEC county • Collect specimens • Culture and PCR (use recommended methods, materials) • Begin treatment (do not wait for lab confirmation)

  39. Pertussis Case Investigation • Identify contacts during infectious period • Most infectious at cough onset through 21 days after cough onset • Close contacts should receive antibiotic prophylaxis, regardless of vaccination • Pertussis is highly infectious • Use standard and droplet precautions • Consider face masks to all patients with URI (flu, pertussis, etc) • Cases must stay home until completion of 5 days of antibiotics

  40. Clinicians and Pertussis • Use recommended methods to diagnose and treat suspected cases • Early diagnosis and treatment will prevent infant cases and deaths • Use postpartum cocooning strategies to vaccinate parents, families of newborns before mother is discharge • Ensure patients are appropriately vaccinated with DTaP and Tdap

  41. Pertussis Vaccines:Got Tdap?

  42. Pertussis Vaccines • DTaP • Infant/childhood vaccine • Ages 6 weeks to 6 years • Tdap • Adolescent/Adult vaccine • Ages 10 to 64 years • Group in whom studies were done • No licensed vaccine for those 7-9 years of age • Some off label use reported for >64 year olds

  43. Pertussis Vaccines Ref: Sandora et al. Clin Microbiol Rev. 2008:21(3);426-434.

  44. DTaP Adverse Reactions • Local reactions • Temp of 101° or higher • More severe adverse reactions not common • Local reactions and fever more common following 4th and 5th doses (swelling involving entire thigh or upper arm has been reported—NOT a contraindication to 5th dose)

  45. DTaP Precautions • Moderate or severe acute illness • Temperature 105° (40.5° C.) or higher within 48 hours with no other identifiable cause • Collapse or shock-like state (hypotonic hyporesponsive episode) within 48 hours • Persistent, inconsolable crying lasting 3 hours or longer, occurring within 48 hours • Convulsions with or without fever occurring within 3 days

  46. DTaP/Tdap Contraindications • Severe allergic reaction (anaphylaxis) to vaccine component or following a prior dose • Encephalopathy not due to another identifiable cause occurring within 7 days after vaccination with a pertussis-containing vaccine

  47. Tdap in Persons with Adverse Events after DTaP • Occurrence of adverse reactions (precaution) following DTaP vaccine in childhood is NOT a contraindication or precaution to administration of Tdap to an adolescent or adult

  48. Tdap Precautions • History of a severe local reaction (Arthus reaction) following a prior dose of a tetanus and/or diphtheria toxoid-containing vaccine • Progressive neurologic disorder until the condition has stabilized • History of Guillain-Barré syndrome within 6 weeks after a prior dose of tetanus toxoid-containing vaccine • Moderate or severe acute illness

  49. Tdap Adverse Reactions • Local reactions 21%-75% (pain, redness, swelling) • Temp of 100.4oF 3%-5% or higher • Adverse reactions occur at approximately the same rate as Td alone

  50. Tdap Recommendations • Approved as a single booster to replace Td in persons fully vaccinated with pediatric DTaP or DTP • Routine administration at 11-12 year well visit. • Adolescents and adults <65 years of age who have not received a dose of Tdap, or for whom vaccine status is unknown, should be immunized as soon as feasible. • Priority groups • Health care personnel (HCP) • Any individual with infant contact (<1 year of age) • Use Tdap for wound prophylaxis, not Td, if not already received Tdap

More Related